We build the clinical, economic, and journey evidence that moves therapies from label to lived care, and the pathways that make national programs actually work at scale in Egypt and MENA.
Access decisions in Egypt aren’t made in silos. Evidence, market access, and the patient journey either move together, or the therapy stalls between label and prescription.
HEOR, real-world evidence, epidemiology, and burden-of-illness models sized for Egyptian and MENA payer realities: not imported dossiers.
Payer value stories, pricing corridors, formulary positioning, and reimbursement pathways, built for HIO, MoHP, and private-sector realities.
End-to-end pathway design from screening to specialist care, stratified, dimensioned, and engineered to work at population scale.
MENA is not one market, and no single access playbook survives crossing a border. Saudi Arabia decides through CHI and NUPCO. The UAE runs on DoH and Daman logic. Egypt is being rewritten in real time by UHIA, EDA, UPA, and HIO. Kuwait’s MoH sets its own rhythm. Each body reads evidence differently, prices differently, and defines “value” differently. A dossier built for a regional average lands nowhere, the work is country-by-country, payer-by-payer, or it doesn’t land at all.
Each stage feeds the next, and the last feeds the first. Nothing is left as a standalone deliverable.
Local epidemiology, burden modeling, cost-of-illness, and RWE positioning, sized for the actual Egyptian care system, not a global average.
Payer value story, pricing corridor, HIO/private-sector positioning, formulary path, and reimbursement architecture built for local decision-makers.
Stratified pathway design from screening through specialist care. Every step dimensioned, sequenced, and made ready to hand to an operational team.
MoHP, HIO, medical societies, and payer alignment, the political and clinical consensus that turns a pathway into policy.
CEA — CUA — BIA — COI — CMA — CBA. Six health economic evaluation formats delivered as structured capability-build programs, scoped, priced, and executed by a regional team that understands what Egyptian and MENA payers actually accept as evidence — built as a service.
Markov and decision-tree models comparing your therapy against standard of care, ICER, life-years gained, and sensitivity analyses calibrated to Egyptian cost data and WTP thresholds.
QALY-based comparisons for therapies whose value sits in quality-adjusted life-years, not just cost per event. The evaluation payers ask for when the therapy changes how patients live.
5-year payer-perspective forecasts of incremental spend, drug-mix shift, and downstream savings, formatted for HIO, MoHP, UPA, and private-insurer submission.
Full economic burden of a disease across direct medical, direct non-medical, and indirect (productivity) costs, the baseline a payer needs before considering incremental spend.
Head-to-head cost comparison for therapies with equivalent clinical outcomes, the sharpest, fastest evaluation when efficacy is settled and the price question isn't.
Monetized comparison of costs and benefits, the evaluation for cross-programme decisions where value must be expressed in a single currency, not just health outcomes.
Two anchor cases, each solving a different piece of the integrated value puzzle at national scale.
Integrated Value work has the highest impact where the access equation is hardest, high price, complex pathway, or a payer who needs to see the local math.
HPP, NF1, and other rare indications where small patient counts, high therapy cost, and payer skepticism demand a locally-built HEE story.
Where guideline-changing therapies land against high-cost comparators, and payer-grade budget impact modeling decides the reimbursement outcome.
Anemia, obesity, short-stature, and hepatitis programs where the case for scale depends on patient-pathway design and outcomes tracking.
Where CKD progression, dialysis cost trajectories, adherence pathway design, and long-horizon cost-utility modeling shift the conversation from unit price to lifetime value.
Ministry of Health — Drug Regulator — Pricing & Procurement — National Payer — Private Insurers — Medical Societies. Same six gates, under different names.
HEOR that lands is HEOR built for the body that has to accept it, and across the region, each market’s version of that body reads cost, value, and evidence differently.
The framework is built market-by-market; our executed anchor cases to date are Egyptian, with the wider MENA gates mapped for entry.
National policy scope, MoHP, MoH, DoH and peers.
Evidence acceptance, EDA, SFDA, DHA and peers.
Pricing and procurement, UPA, NUPCO and peers.
Reimbursement logic, HIO, CHI, Daman and peers.
Parallel formulary and pricing, Bupa Arabia, GIG, Sukoon and peers.
Clinical consensus, Medical Syndicate, SCFHS, EMA and peers.
The same senior-led discipline that runs our other service lines, applied to the access and evidence decision.
A HEOR boutique stops at the dossier; an access agency runs the payer conversation alone; another team maps the patient journey separately. Roadmap connects evidence, access, and patient pathway in one integrated strategy: not three disconnected deliverables.
Delivered by the founding team: no junior handoff, no matrix hand-through. On an access decision that determines whether a therapy reaches patients, a wrong evidence framing or misread payer signal costs a full submission cycle to unwind.
Grounded in how MENA institutions actually decide, Saudi’s CHI and NUPCO, the UAE’s DoH and Daman, Egypt’s UPA, EDA, and HIO: not a regional-average template. That fluency keeps a dossier from being built for the wrong market.
Evidence creates value only when it can influence what happens next. A reimbursement, a value story, a policy pathway, a patient access strategy, each requires more than rigorous analysis. It requires the connection between evidence, context, and action. This is where Roadmap works.
When the Decision is the ChallengeFive recurring situations across MENA pharma leadership, where evidence exists, but the decision still doesn’t.
The clinical case is proven. What’s missing is the value narrative payers, policymakers, and stakeholders can act on. We rebuild the story so it answers the question actually being asked, from the same evidence base.
Reimbursement, HTA, listing, funding, the pathways are many, and rarely obvious. We map the routes, weigh the trade-offs, and design the access strategy that fits the market and the moment.
Clinical, economic, epidemiological, patient, and policy evidence often live in separate silos. We connect them into a single evidence architecture, built around the decision it needs to support.
A new regulation, a new comparator, a new payer stance, access strategies age quickly. We help you reassess the pathway and adjust before the shift becomes a setback.
Good analysis without a clear next step is a common failure of consulting. We close the gap between what the evidence says and what needs to happen, with a defined move, a defined owner, and a defined outcome.
Access strategies age quickly. The strongest ones anticipate the shift. — The Roadmap Principle
This isn’t another evidence dossier. It’s the route from what you know to what happens next.
Government bodies, payer authorities, national programs, and sponsors that have anchored, and sponsored, Roadmap's Integrated Value work in Egypt.
We work in two directions here — building the payer-facing value case for pharma sponsors, and designing the clinical pathways that national programs and health authorities run on.
